Role of Worry in Addiction: Implication of Metacognitive Beliefs and Type 2 Worry
ABSTRACT Introduction According to the self‐medication hypothesis, worriers use substances to cope with their symptoms; however, some published results have challenged this hypothesis. The aim of this study is to show if worry increases the risk of SUD when it is negatively appraised by negative met...
Saved in:
Published in: | Clinical psychology and psychotherapy Vol. 31; no. 5; pp. e3048 - n/a |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
John Wiley and Sons, Limited
01-09-2024
Wiley |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ABSTRACT
Introduction
According to the self‐medication hypothesis, worriers use substances to cope with their symptoms; however, some published results have challenged this hypothesis. The aim of this study is to show if worry increases the risk of SUD when it is negatively appraised by negative metacognitive beliefs.
Method
We recruited three samples: 68 patients with a severe AUD, 27 patients dependent on eating and 42 control participants. We used the Yale Food Addiction Scale‐2, the Metacognitions Questionnaire‐65, the UPPS‐P Impulsive Behaviour Scale and the Anxiety Thoughts Inventory.
Results
We confirmed a direct effect of worries and metaworry on alcohol (AUD) and eating addiction (EA), but our multivariate analyses revealed that metacognitive beliefs and metaworry are the most robust predictors of alcohol and eating addiction.
Discussion
We reported substance‐related differences in the relationship between worry and addiction. AUD is related to the metacognitive activity set in motion by worries while EA is associated with a maladaptive form of worry (meta‐worry) where worries are negatively interpreted. |
---|---|
Bibliography: | : Priscillia Improvisato: PhD. Student, Laboratory Epsylon (EA4556), University of Paul Valéry Montpellier 3, Montpellier; Raphaël Trouillet, PhD, Assistant Professor, Laboratory Epsylon (EA4556), University of Paul Valéry Montpellier 3, Montpellier; Sophie Schuldiner: M.D., PhD., VBIC, INSERM U1047, Univ Montpellier, Service Des Maladies Métaboliques Et Endocriniennes, CHU Nîmes, Clinique du Pied Gard Occitanie, Route de Carnon, 30240, Le Grau du Roi, France.; Amandine Luquiens: M.D., PhD, Department of Addictology, CHU Nîmes, Univ Montpellier, Nîmes, France, CESP, Univ. Paris‐Sud, UVSQ, INSERM, Université Paris‐Saclay, Villejuif, France; Tristan Hamonnière: PhD, UR Clipsyd, Université Paris Nanterre, Nanterre, France; Hélène Donnadieu: M.D., PhD., Department of Addictology, Montpellier University Hospital, Montpellier, France, Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM U1058, EFS, CHU Montpellier, Montpellier, France; Pascal Perney: M.D., PhD, Addictions Department, CHU Caremeau, Nîmes, France, Inserm U1018, Hôpital Paul Brousse, Villejuif, France. Authors note ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1063-3995 1099-0879 1099-0879 |
DOI: | 10.1002/cpp.3048 |